Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- EyeGene Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06099613
- Locations
- 🇦🇺
Nucleus Network Pty Ltd- Melbourne, Melbourne, Victoria, Australia
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- EyeGene Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05188469
- Locations
- 🇦🇺
Holdsworth House, Sydney, New South Wales, Australia
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Prevention of Herpes Zoster (HZ)
- Interventions
- Drug: Treatment 2 (EG-HZ-002)Drug: Treatment 1 (EG-HZ-001)Drug: Treatment 3 (EG-HZ-003)Drug: Treatment 4 (EG-HZ-004)Drug: Treatment 5
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- EyeGene Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04210752
- Locations
- 🇦🇺
Q-Pharm Pty Ltd (Nucleus Network), Herston, Queensland, Australia
News
No news found